Amanta Healthcare (NSE:AMANTA) EBIT: ₹307 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AMANTA Amanta Healthcare Ltd NSE:AMANTA
26 GF Score
Price ₹175.59
! 4 Warning Signs
View Full Analysis

What is Amanta Healthcare EBIT?

Amanta Healthcare NSE:AMANTA -2.00% 26 EBIT is ₹307 Mil as of Mar. 2026. GuruFocus rates NSE:AMANTA with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Amanta Healthcare's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹119 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹307 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Amanta Healthcare's annualized ROC % for the quarter that ended in Mar. 2026 was 6.95%. Amanta Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.95%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Amanta Healthcare's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.68%.

Amanta Healthcare  (NSE:AMANTA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Amanta Healthcare's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=408.04 * ( 1 - 27.38% )/( (0 + 4260.832)/ 1 )
=296.318648/4260.832
=6.95 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5579.807 - 389.537 - ( 929.438 - max(0, 1410.568 - 2385.274+929.438))
=4260.832

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Amanta Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=474.524/( ( (0 + max(0, 0)) + (2880.111 + max(784.962, 0)) )/ 1 )
=474.524/( ( 0 + 3665.073 )/ 1 )
=474.524/3665.073
=12.95 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(430.235 + 827.094 + 193.436) - (389.537 + 0 + 276.266)
=784.962

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Amanta Healthcare's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=306.569/8333.041
=3.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amanta Healthcare EBIT Related Terms

Amanta Healthcare EBIT Historical Data

* Premium members only.

The historical data trend for Amanta Healthcare's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amanta Healthcare EBIT Chart

Amanta Healthcare Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
1,048.45 370.75 377.86 426.55 418.70

Amanta Healthcare Quarterly Data
Mar22 Mar23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only 114.27 144.31 74.29 113.64 118.63

NSE:AMANTA vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amanta Healthcare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amanta Healthcare EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amanta Healthcare's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Amanta Healthcare's EV-to-EBIT falls into.


NSE:AMANTA
26GF Score
Amanta Healthcare Ltd NSE:AMANTA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amanta Healthcare EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹307 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹307 Mil mean?
Amanta Healthcare (NSE:AMANTA) has a EBIT of ₹307 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Amanta Healthcare.
Is Amanta Healthcare's EBIT too high?
Amanta Healthcare's current EBIT is ₹307 Mil. Overall, Amanta Healthcare has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Amanta Healthcare's EBIT compare to ZTS and UTHR?
Amanta Healthcare's EBIT of ₹307 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Amanta Healthcare. Amanta Healthcare's current EBIT is ₹307 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amanta Healthcare stock overvalued right now?
Amanta Healthcare (NSE:AMANTA) has a current EBIT of ₹307 Mil. The current EBIT is ₹307 Mil. Amanta Healthcare's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Amanta Healthcare (NSE:AMANTA), the current EBIT is ₹307 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amanta Healthcare Business Description

Other Exchanges 544502:India
Address C.J. Marg, 8th Floor, Shaligram Corporates, Ambli, Ahmedabad, GJ, IND, 380058
Amanta Healthcare Ltd is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal and Injection Strech Blow Moulding technology. It manufactures large volume parenterals and small volume parenterals in six therapeutic segments. It also manufactures medical devices. The company manufactures fluid therapy, formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc. in medical device segment. It offers wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume till 1000 ml.
26GF Score

Get the complete analysis for NSE:AMANTA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹175.59
Price